Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (October 2021)
23 slides from Century Therapeutics's investor presentation, Oct 13, 2021
Slide 1: Corporate Overview October 2021
CORPORATE OVERVIEW October 2021
Slide 2: Forward-Looking Statements
2 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts
Slide 3: Century Therapeutics - Emerging Leader in iPSC Cell Therapies
3 3 CENTURY THERAPEUTICS - EMERGING LEADER IN iPSC CELL THERAPIES EMPLOYEES INCLUDING EXPERIENCED LEADERS AND ENTREPRENEURS ~120 COMPREHENSIVE iPSC CELL PLATFORM FOR IMMUNE EFFECTOR CELLS LEAD PROGRAM ON TRACK TO FILE IND IN MID 2022 STATE-OF-THE ART GMP MANUFACTURING FACILITY EXPECTED TO BE OPERATI
Slide 4: We Are Building a Next Generation Cell Therapy Platform
4 4 Not for further distribution WE ARE BUILDING A NEXT GENERATION CELL THERAPY PLATFORM Autologous (Patient derived) Allogeneic (Healthy donor derived) iPSC derived • Receptive to complex genetic editing • Significant replication capacity • Streamlined manufacturing and consistent product • Lengthy
Slide 5: Proven Leadership Team
5 5 Osvaldo (Lalo) Flores, CEO Hy Levitsky, President R&D Adrienne Farid, COO Greg Russotti, CTO Luis Borges, CSO Michael Diem, CBO PROVEN LEADERSHIP TEAM
Slide 6: Foundational Investments in iPSC Know-How and Manufacturing
6 6 FOUNDATIONAL INVESTMENTS IN iPSC KNOW- HOW AND MANUFACTURING 6 In-House Manufacturing accelerates learnings and enables faster product iteration • Century facility expected to be operational by early 2022 • 53,000 ft2 facility • Designed to produce multiple immune cell types • Two sites provides
Slide 7: Cryopreserved Drug Product Potentially Enables Immediate Dosing at Clinical Sites
7 7 Not for further distribution CRYOPRESERVED DRUG PRODUCT POTENTIALLY ENABLES IMMEDIATE DOSING AT CLINICAL SITES Cell Source Formulation Freezing Storage Thawing Dilution Administration Cryopreservative Freezing Dilution Thaw 2 3 4 5 Cell State 1 Ready for immediate thawing and dosing at hospital
Slide 8: iPSC Technology Can Overcome Limitations of Donor Derived Platforms
8 8 Allogeneic, donor-derived Multiple donors Fewer doses per batch • Complex manufacturing, heterogeneous product, limited scale • Limited genetic engineering options Allogeneic, iPSC-derived Greater doses per batch • Efficient manufacturing, homogeneous product, greater scale • Likely unlimited ge
Slide 9: Integrated Cell Engineering and Manufacturing
9 9 INTEGRATED CELL ENGINEERING AND MANUFACTURING Precision editing • Proprietary, high efficiency CRISPR-mediated homology directed repair reduces off-target integration • Stepwise gene editing avoids risky multiplex modification and structural variants • Safety switch enables elimination if necess
Slide 10: Century's CRISPR-Mediated iPSC Gene Editing
10 10 CENTURY’S CRISPR-MEDIATED iPSC GENE EDITING Not for further distribution 10 Highly uniform product candidates derived from fully characterized single-cell clones Proprietary CRISPR-MAD7 mediated homology directed repair (HDR) • MAD7 licensed from Inscripta. Methodology developed at Century • H
Slide 11: Century's Differentiated Approach to Optimizing Anti-Tumoral Response
11 11 CENTURY’S DIFFERENTIATED APPROACH TO OPTIMIZING ANTI-TUMORAL RESPONSE Potentially maximizing durability of clinical responses and efficacy and overcome limitations of existing cell therapy technologies Genetic Engineering (To improve fitness) Manufacturing Optimization (To improve product qual
Slide 12: Overcoming Alloreactivity Challenges
12 12 Not for further distribution OVERCOMING ALLOREACTIVITY CHALLENGES Current limitations NK cell, CAR-NK Allogeneic CAR-T GvHD Host vs graft Host vs graft Century’s solution CAR-iNK with Allo-evasionTM CAR-iT with Trusted TCR, Allo-evasionTM Prevention of Graph versus Host Disease • GvHD is circu
Slide 13: Allo-Evasion 1.0 Designed to Overcome Major Pathways of Host vs Graft
13 13 ALLO-EVASIONTM 1.0 DESIGNED TO OVERCOME 3 MAJOR PATHWAYS OF HOST VS GRAFT β2M KO (HLA-I) HLA-E KI CIITA KO (HLA-II) CD8+ T Cell CD4+ T Cell NK cell Deletion of β 2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells Knock out of CIITA eliminates HLA-II
Slide 14: Illustrative Potential of Allo-Evasion on Cellular Pharmacokinetics
14 14 Not for further distribution ILLUSTRATIVE POTENTIAL OF ALLO-EVASIONTM ON CELLULAR PHARMACOKINETICS Repeat doses With Allo-EvasionTM engineering Without Allo-EvasionTM engineering Time Cell count Initial dose Minimum threshold to maintain pharmacological pressure
Slide 15: CNTY-101: CAR-iNK Candidate in R/R B-Cell Lymphoma
15 15 CNTY-101: CAR-iNK CANDIDATE IN R/R B-CELL LYMPHOMA CNTY-101 may change the lymphoma treatment paradigm given its potential: • To treat patients immediately upon diagnosis • To employ milder lymphodepletion regimens • To enhance overall response rate and duration of response based on the antici
Slide 16: iNK Cell Platform Is Our Most Advanced Platform
16 16 iNK CELL PLATFORM IS OUR MOST ADVANCED PLATFORM CNTY-101, our first product candidate is a CAR-iNK cell engineered with multiple features 0 5 10 15 20 0 2.0×108 4.0×108 6.0×108 8.0×108 1.0×109 1.2×109 Day Post-tumor Implantation Average Radiance (p/s/cm²/sr) ± SEM CAR-iNK CAR-iNK CAR-iNK Tumor
Slide 17: Pipeline
17 17 Product iPSC Platform Targets Indications Ownership Expected IND Submission Discovery Preclinical Phase 1 Phase 2 Phase 3 CNTY- 101 iNK CD19 Lymphoma Mid 2022 CNTY- 103 iNK CD133 + EGFR Glioblastoma 1H 2023 CNTY- 102 iT or iNK CD19 + CD79b Lymphoma 2H 2023 CNTY- 104 iT or iNK Multi- specific A
Slide 18: Century iT Cell Platform: TrueT Cells with Trusted TCRs
18 18 CENTURY iT CELL PLATFORM: TrueT CELLS WITH TRUSTED TCRS Not for further distribution Unique features of Century’s iT cell platform: • Retention of a functional TCR intended to improve iT cell differentiation and functionality • Use of Trusted αβ and γδ which are not expected to mediate GVHD Tr
Slide 19: γδ iT Cells Platform Option to Generate TrueT Cells
19 19 Not for further distribution γδ IT CELLS IS ONE OF THE T CELL PLATFORM OPTIONS WE ARE CURRENTLY EXPLORING TO GENERATE TrueT CELLS CAR-iT CELL PLATFORM: γδ CAR-IT CELLS TrueT Cells True CAR-iT cells kill lymphoma cells similarly to peripheral blood CAR-T cells 98.9 CAR 95.2 Differentiation of γ
Slide 20: Our iT Cell Platform Is Closely Behind and Making Demonstrable Progress
20 20 OUR iT CELL PLATFORM IS CLOSELY BEHIND AND MAKING DEMONSTRABLE PROGRESS Developing αβ and γδ iT platforms with Trusted TCRs that are not expected to cause GvHD 0 5 10 15 20 0 5.0×108 1.0×109 1.5×109 2.0×109 2.5×109 Day Post-tumor Implantation Average Radiance (p/s/cm²/sr) ± SEM CAR-iT Tumor on
Slide 21: iPSC-Derived γδ iT Cells Mediate Serial Killing Against Lymphoma Cells
21 21 iPSC-DERIVED γδ iT CELLS MEDIATE SERIAL KILLING AGAINST LYMPHOMA CELLS Not for further distribution 0 25 50 75 100 125 150 175 200 225 250 0 1×106 2×106 3×106 4×106 Time (hours) Incucyte RCU x µ m 2 /well γδ CAR-iT PBMC CAR-T γδ CAR-iT and PBMC CAR-T cells have similar serial killing activity
Slide 22: Catalysts
22 22 CATALYSTS Event Estimated Timing Close IPO with gross proceeds of $243M 2Q21 Solicit Pre-IND written feedback for CNTY-101 3Q21 CNTY-101 enters IND enabling studies and manufacturing 4Q21 cGMP manufacturing facility in Branchburg NJ expected to be fully operational 1Q22 In vivo POC for CNTY-10
Slide 23: Century's Next Generation iPSC Technology Platform
23 23 CENTURY’S NEXT GENERATION iPSC TECHNOLOGY PLATFORM Broad product pipeline with first 1st IND submission targeting Mid- 2022 Precision gene editing Advanced manufacturing Allo-Evasion™ Protein engineering iPSC-derived NK cells iPSC-derived T cells Comprehensive allogeneic iPSC- based cell platf
Century Therapeutics — Investor Presentation (October 2021) on 6ix